Smart ring manufacturer Oura announced an agreement to acquire AI-native primary care company Counsel Health for $625 million. This major consolidation move comes only a few weeks after Oura chose to indefinitely postpone its initial public offering, which could have reached up to $2.2 billion, pointing to ongoing uncertainty in the broader IPO market as the primary driver for the delay.
Counsel Health operates an AI-powered platform that pairs a chat-based medical experience with direct access to licensed physicians. The technology was previously integrated directly into the Oura companion application in June, allowing users to leverage Counsel's medical artificial intelligence for personalized insights and communicate with real doctors when necessary. Following the completion of the acquisition, the two entities intend to scale their collaborative framework to cover preventative medicine, acute care, specialty treatment, and long-term chronic care management.
Key takeaways
- Oura is acquiring Counsel Health for $625 million following the indefinite delay of its IPO.
- Counsel Health's AI medical platform was integrated into the Oura app back in June.
- Counsel CEO Muthu Alagappan will transition to Oura as chief clinical AI officer alongside 70 employees.
- Oura reported impressive financial growth, reaching $1.75 billion in revenue for fiscal year 2026.
Expanding Beyond Hardware into Healthcare Services
While Oura has maintained a leading position in the consumer smart ring market for years, increasing competition from emerging rivals like RingConn and Ultrahuman has driven the company to accelerate its innovation pipeline. By bringing Counsel Health in-house, Oura broadens its operational scope beyond wearable hardware to help its user base directly access professional medical services. Oura CEO Tom Hale noted in a press release that members can leverage Counsel to take tangible action on their physiological data across numerous needs, ranging from minor health questions and prescription management to complex lab results and chronic care referrals.
Counsel Health previously secured a $25 million Series A funding round a year prior, backed by prominent investors Andreessen Horowitz and GV, bringing its estimated total historical funding to approximately $36 million. Post-acquisition, Counsel will continue servicing both current and new enterprise partners, with a stated mission to expand its artificial intelligence-driven care model to a wider demographic outside of standard Oura memberships.
Leadership Transition and Strong Financial Performance
As part of the structural integration, Counsel CEO Muthu Alagappan will join Oura as chief clinical AI officer, bringing approximately 70 employees with him. Alagappan emphasized that the platform was engineered around trust, safety, and accountability, maintaining active physician involvement for all major clinical choices. The transaction is formally scheduled to close before the end of 2027.
The acquisition announcement coincided with the disclosure of significant financial growth for the wearable tech company. Oura recorded a 153% year-over-year revenue increase to $533 million for the quarter ending September 30. For the full fiscal year 2026, the company brought in approximately $1.75 billion, representing 92% year-over-year growth. These figures follow a $900 million late-stage funding round in October 2025 that pushed Oura's valuation to $11 billion.
Comments